Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Creatine for Depression in Methamphetamine Users
NCT02568878Phase 3Recruiting
- Sponsor
- Montana State University
- Start
- Nov 2015
- Primary completion
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of creatine in major depressive disorder (MDD), anxiety disorder and methamphetamine use disorder (MUD), sponsored by Montana State University. Primary endpoints: Hamilton Depression Rating Scale at 8 weeks and Hamilton Anxiety Rating Scale at 8 weeks. Started Nov 2015; status: recruiting.
02
Drugs
creatine
03
Conditions
major depressive disorder (MDD)anxiety disordermethamphetamine use disorder (MUD)
Beyond the preview
Go deeper on NCT02568878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02568878.